7.6.2021 B9-0306/2021 } B9-0307/2021 } B9-0309/2021 } B9-0311/2021 } RC1/Am. 24 Amendment 24 Manon Aubry, Marc Botenga, Kateřina Konečná, Dimitrios Papadimoulis, Marisa Matias, João Ferreira, Helmut Scholz on behalf of The Left Group Joint motion for a resolution PPE, S&D, Renew, Verts/ALE Meeting the global COVID-19 challenge: effects of the waiver of the WTO TRIPS Agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries Joint motion for a resolution Citation 12 a (new) Joint motion for a resolution Amendment – having regard to its resolution of 19 May 2021 on accelerating progress and tackling inequalities towards ending AIDS as a public health threat by 20301a, __________________________ 1a Texts adopted, P9_TA(2021)0250. Or. en AM\1233632EN.docx PE692.580v01-00 } PE694.416v01-00 } PE694.418v01-00 } PE694.420v01-00 } RC1 EN United in diversityEN 7.6.2021 B9-0306/2021 } B9-0307/2021 } B9-0309/2021 } B9-0311/2021 } RC1/Am. 25 Amendment 25 Marc Botenga, Kateřina Konečná, Manon Aubry, Marisa Matias, João Ferreira on behalf of The Left Group Joint motion for a resolution PPE, S&D, Renew, Verts/ALE Meeting the global COVID-19 challenge: effects of the waiver of the WTO TRIPS Agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries Joint motion for a resolution Recital B a (new) Joint motion for a resolution Amendment Ba. whereas the Declaration on the TRIPS Agreement and Public Health, adopted in Doha on 14 November 2001, states that the TRIPS Agreement should be implemented and interpreted in a way that is good for public health – encouraging both access to existing medicines and the development of new ones; whereas the WTO TRIPS Council decided on 6 November 2015 to extend the drug patent exemption for the least developed countries (LDCs) until January 2033; Or. en AM\1233632EN.docx PE692.580v01-00 } PE694.416v01-00 } PE694.418v01-00 } PE694.420v01-00 } RC1 EN United in diversityEN 7.6.2021 B9-0306/2021 } B9-0307/2021 } B9-0309/2021 } B9-0311/2021 } RC1/Am. 26 Amendment 26 Marc Botenga, Kateřina Konečná, Manon Aubry, Marisa Matias, João Ferreira on behalf of The Left Group Joint motion for a resolution PPE, S&D, Renew, Verts/ALE Meeting the global COVID-19 challenge: effects of the waiver of the WTO TRIPS Agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries Joint motion for a resolution Recital B b (new) Joint motion for a resolution Amendment Bb. whereas more than 200 000 EU citizens have already supported the European Citizens’ Initiative ‘no profit on pandemic’, which aims to make anti- pandemic vaccines and treatments a global public good, freely accessible to everyone; Or. en AM\1233632EN.docx PE692.580v01-00 } PE694.416v01-00 } PE694.418v01-00 } PE694.420v01-00 } RC1 EN United in diversityEN 7.6.2021 B9-0306/2021 } B9-0307/2021 } B9-0309/2021 } B9-0311/2021 } RC1/Am. 27 Amendment 27 Marc Botenga, Kateřina Konečná, Manon Aubry, Marisa Matias, João Ferreira on behalf of The Left Group Joint motion for a resolution PPE, S&D, Renew, Verts/ALE Meeting the global COVID-19 challenge: effects of the waiver of the WTO TRIPS Agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries Joint motion for a resolution Recital F Joint motion for a resolution Amendment F. whereas huge amounts of private F. whereas huge amounts of private and public funds and resources have been and public funds and resources have been invested in research and development, invested in research and development, clinical trials and procurement in order to clinical trials and procurement in order to develop vaccines and COVID-19 develop vaccines and COVID-19 treatments in an open and accessible way; treatments in an open and accessible way; whereas private and public sector research, whereas private and public sector research, health institutions, frontline workers, health institutions, frontline workers, scientists, researchers and patients have all scientists, researchers and patients have all gathered information on the virus, which gathered information on the virus, which pharmaceutical companies have utilised; pharmaceutical companies have utilised; calls on the Commission to ensure that research results fully or partially funded by EU programmes or other public funds, including the future HERA, remain in the public domain or are subject to non-exclusive licensing; Or. en AM\1233632EN.docx PE692.580v01-00 } PE694.416v01-00 } PE694.418v01-00 } PE694.420v01-00 } RC1 EN United in diversityEN 7.6.2021 B9-0306/2021 } B9-0307/2021 } B9-0309/2021 } B9-0311/2021 } RC1/Am. 28 Amendment 28 Marc Botenga, Kateřina Konečná, Manon Aubry, Marisa Matias, João Ferreira, Helmut Scholz on behalf of The Left Group Joint motion for a resolution PPE, S&D, Renew, Verts/ALE Meeting the global COVID-19 challenge: effects of the waiver of the WTO TRIPS Agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries Joint motion for a resolution Recital H Joint motion for a resolution Amendment H. whereas many developing countries H. whereas many developing countries with insufficient or no manufacturing with insufficient or no manufacturing capacity still face significant political capacity still face significant political pressure and legal difficulties preventing pressure and legal difficulties preventing their use of TRIPS flexibilities, notably their use of TRIPS flexibilities, notably Article 31bis and the cumbersome and Article 31bis and the cumbersome and lengthy process for the import and export lengthy process for the import and export of pharmaceutical products; of pharmaceutical products; recalls the critical need both for global health and global supply chains to develop local capacities in developing countries, notably in terms of pharmaceutical research, development and production, in order to bridge the persisting gap in research and medicines production through product- development partnerships and the creation of open centres of research and production; Or. en AM\1233632EN.docx PE692.580v01-00 } PE694.416v01-00 } PE694.418v01-00 } PE694.420v01-00 } RC1 EN United in diversityEN 7.6.2021 B9-0306/2021 } B9-0307/2021 } B9-0309/2021 } B9-0311/2021 } RC1/Am. 29 Amendment 29 Marc Botenga, Kateřina Konečná, Manon Aubry, Marisa Matias, João Ferreira on behalf of The Left Group Joint motion for a resolution PPE, S&D, Renew, Verts/ALE Meeting the global COVID-19 challenge: effects of the waiver of the WTO TRIPS Agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries Joint motion for a resolution Recital I Joint motion for a resolution Amendment I. whereas patent and other I. whereas patent and other intellectual property protections ensure intellectual property rights, notably trade safeguards for entrepreneurial risk- secrets, can hamper or delay future taking, and a multilateral intellectual research by creating data silos; calls on property rights (IPR) legal framework the Commission to promote an innovation provides incentives which are critical for ecosystem better set up for using collective preparedness against future pandemics; intelligence to accelerate advances; highlights the need to use collective intelligence to accelerate advances, making wider use of open science, patent pools and compulsory licensing; calls on the Commission to support measures favouring open science in order to accelerate the sharing of data and research results within the scientific community in Europe and beyond; Or. en AM\1233632EN.docx PE692.580v01-00 } PE694.416v01-00 } PE694.418v01-00 } PE694.420v01-00 } RC1 EN United in diversityEN 7.6.2021 B9-0306/2021 } B9-0307/2021 } B9-0309/2021 } B9-0311/2021 } RC1/Am. 30 Amendment 30 Manon Aubry, Marc Botenga, Kateřina Konečná, Dimitrios Papadimoulis, Marisa Matias, João Ferreira, Helmut Scholz on behalf of The Left Group Joint motion for a resolution PPE, S&D, Renew, Verts/ALE Meeting the global COVID-19 challenge: effects of the waiver of the WTO TRIPS Agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries Joint motion for a resolution Recital I a (new) Joint motion for a resolution Amendment Ia. whereas during a pandemic and epidemic, the right to health should prevail over the right to profit, and patents must not be an obstacle to the production of vaccines and medicines to save lives or be used to make extra profits and gains; Or. en AM\1233632EN.docx PE692.580v01-00 } PE694.416v01-00 } PE694.418v01-00 } PE694.420v01-00 } RC1 EN United in diversityEN 7.6.2021 B9-0306/2021 } B9-0307/2021 } B9-0309/2021 } B9-0311/2021 } RC1/Am. 31 Amendment 31 Manon Aubry, Marc Botenga, Kateřina Konečná, Dimitrios Papadimoulis, Marisa Matias, João Ferreira, Helmut Scholz on behalf of The Left Group Joint motion for a resolution PPE, S&D, Renew, Verts/ALE Meeting the global COVID-19 challenge: effects of the waiver of the WTO TRIPS Agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries Joint motion for a resolution Recital J a (new) Joint motion for a resolution Amendment Ja. whereas the polio vaccine was brought onto the markets patent-free and the disease has now been eradicated in many regions of the world; whereas the South African Government led by Nelson Mandela was forced to use the availability of compulsory licensing to push for affordable and quality generic equivalents in order to avoid paying exorbitant prices to multinational drug companies using patents for HIV treatment; Or. en AM\1233632EN.docx PE692.580v01-00 } PE694.416v01-00 } PE694.418v01-00 } PE694.420v01-00 } RC1 EN United in diversityEN 7.6.2021 B9-0306/2021 } B9-0307/2021 } B9-0309/2021 } B9-0311/2021 } RC1/Am.